Oncolytics Biotech, Inc. (ONCY) Appoints Dr. Alan Warrander as Senior Vice President, Global Licensing and Business Development
Oncolytics Biotech, Inc., a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, recently announced that the company has appointed Dr. Alan Warrander to the role of senior vice president of global licensing and business development. In this position, Dr. Warrander will manage the execution of the global licensing strategy for REOLYSIN®, the company’s proprietary formulation of the human reovirus. Retaining more than 32 years of experience with biotechnology and pharmaceutical companies, Dr. Warrander most recently served as the director of global licensing at AstraZeneca. Dr. Warrander earned his Ph.D. from the University of Birmingham…